Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 92

Similar articles for PubMed (Select 20633016)

1.

Pharmacological modulation by celecoxib of cachexia associated with experimental arthritis and atherosclerosis in rabbits.

Romero FI, Martínez-Calatrava MJ, Sánchez-Pernaute O, Gualillo O, Largo R, Herrero-Beaumont G.

Br J Pharmacol. 2010 Nov;161(5):1012-22. doi: 10.1111/j.1476-5381.2010.00957.x.

2.

The select cyclooxygenase-2 inhibitor celecoxib reduced the extent of atherosclerosis in apo E-/- mice.

Jacob S, Laury-Kleintop L, Lanza-Jacoby S.

J Surg Res. 2008 May 1;146(1):135-42. Epub 2007 Oct 22.

PMID:
17950326
3.

Celecoxib, a selective cyclooxygenase-2 inhibitor, decreases monocyte chemoattractant protein-1 expression and neointimal hyperplasia in the rabbit atherosclerotic balloon injury model.

Wang K, Tarakji K, Zhou Z, Zhang M, Forudi F, Zhou X, Koki AT, Smith ME, Keller BT, Topol EJ, Lincoff AM, Penn MS.

J Cardiovasc Pharmacol. 2005 Jan;45(1):61-7.

PMID:
15613981
4.

Effect of chondroitin sulphate in a rabbit model of atherosclerosis aggravated by chronic arthritis.

Herrero-Beaumont G, Marcos ME, Sánchez-Pernaute O, Granados R, Ortega L, Montell E, Vergés J, Egido J, Largo R.

Br J Pharmacol. 2008 Jun;154(4):843-51. doi: 10.1038/bjp.2008.113. Epub 2008 Apr 21.

5.

Effect of a high dose of glucosamine on systemic and tissue inflammation in an experimental model of atherosclerosis aggravated by chronic arthritis.

Largo R, Martínez-Calatrava MJ, Sánchez-Pernaute O, Marcos ME, Moreno-Rubio J, Aparicio C, Egido J, Herrero-Beaumont G.

Am J Physiol Heart Circ Physiol. 2009 Jul;297(1):H268-76. doi: 10.1152/ajpheart.00142.2009. Epub 2009 May 1.

6.

Celecoxib, a selective cyclooxygenase-2 inhibitor for the treatment of rheumatoid arthritis and osteoarthritis.

Goldenberg MM.

Clin Ther. 1999 Sep;21(9):1497-513; discussion 1427-8. Review.

PMID:
10509845
7.

Chronic arthritis aggravates vascular lesions in rabbits with atherosclerosis: a novel model of atherosclerosis associated with chronic inflammation.

Largo R, Sánchez-Pernaute O, Marcos ME, Moreno-Rubio J, Aparicio C, Granado R, Ortega L, Egido J, Herrero-Beaumont G.

Arthritis Rheum. 2008 Sep;58(9):2723-34. doi: 10.1002/art.23765.

8.

Micro-CT imaging analysis for the effect of celecoxib, a cyclooxygenase-2 inhibitor, on inflammatory bone destruction in adjuvant arthritis rats.

Noguchi M, Kimoto A, Sasamata M, Miyata K.

J Bone Miner Metab. 2008;26(5):461-8. doi: 10.1007/s00774-008-0855-3. Epub 2008 Aug 30.

PMID:
18758904
9.

Effect of celecoxib, a cyclooxygenase-2 inhibitor, on the pathophysiology of adjuvant arthritis in rat.

Noguchi M, Kimoto A, Kobayashi S, Yoshino T, Miyata K, Sasamata M.

Eur J Pharmacol. 2005 Apr 25;513(3):229-35. Epub 2005 Apr 21.

PMID:
15862805
10.

Experimental arthritis inhibits the insulin-like growth factor-I axis and induces muscle wasting through cyclooxygenase-2 activation.

Granado M, Martín AI, Villanúa MA, López-Calderón A.

Am J Physiol Endocrinol Metab. 2007 Jun;292(6):E1656-65. Epub 2007 Feb 6.

11.
12.

Outcome of specific COX-2 inhibition in rheumatoid arthritis.

Lipsky PE, Isakson PC.

J Rheumatol Suppl. 1997 Jul;49:9-14. Review.

PMID:
9249645
13.

Chrysin alleviates testicular dysfunction in adjuvant arthritic rats via suppression of inflammation and apoptosis: comparison with celecoxib.

Darwish HA, Arab HH, Abdelsalam RM.

Toxicol Appl Pharmacol. 2014 Sep 1;279(2):129-40. doi: 10.1016/j.taap.2014.05.018. Epub 2014 Jun 14.

PMID:
24932515
14.

Effectiveness of cyclooxygenase-2 inhibition in limiting abdominal aortic aneurysm progression in mice correlates with a differentiated smooth muscle cell phenotype.

Mukherjee K, Gitlin JM, Loftin CD.

J Cardiovasc Pharmacol. 2012 Dec;60(6):520-9. doi: 10.1097/FJC.0b013e318270b968.

PMID:
22967986
16.

COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma. Celecoxib influences MDSC function.

Veltman JD, Lambers ME, van Nimwegen M, Hendriks RW, Hoogsteden HC, Aerts JG, Hegmans JP.

BMC Cancer. 2010 Aug 30;10:464. doi: 10.1186/1471-2407-10-464.

17.

Dose and time-dependent effects of cyclooxygenase-2 inhibition on fracture-healing.

Simon AM, O'Connor JP.

J Bone Joint Surg Am. 2007 Mar;89(3):500-11.

PMID:
17332098
18.

Celecoxib for the treatment of pain and inflammation: the preclinical and clinical results.

Tindall E.

J Am Osteopath Assoc. 1999 Nov;99(11 Suppl):S13-7. Review.

PMID:
10643176
20.

Phase II nonrandomized study of the efficacy and safety of COX-2 inhibitor celecoxib on patients with cancer cachexia.

Mantovani G, Macciò A, Madeddu C, Serpe R, Antoni G, Massa E, Dessì M, Panzone F.

J Mol Med (Berl). 2010 Jan;88(1):85-92. doi: 10.1007/s00109-009-0547-z. Epub 2009 Oct 3.

PMID:
19802504
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk